Evolving Insights Into the Biological Function and Clinical Significance of Long Noncoding RNA in Glioblastoma

Kun Liu¹, Hong Chen², Yuanyuan Wang³, Liping Jiang⁴,⁵* and Yi Li²*

¹Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States, ²Department of Oncology, 920th Hospital of Joint Logistics Support Force, Teaching Hospital of Kunming Medical University, Kunming, China, ³Department of Pathology, 920th Hospital of Joint Logistics Support Force, Teaching Hospital of Kunming Medical University, Kunming, China, ⁴Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming, China, ⁵Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, United States

Glioblastoma (GBM) is one of the most prevalent and aggressive cancers worldwide. The overall survival period of GBM patients is only 15 months even with standard combination therapy. The absence of validated biomarkers for early diagnosis mainly accounts for worse clinical outcomes of GBM patients. Thus, there is an urgent requirement to characterize more biomarkers for the early diagnosis of GBM patients. In addition, the detailed molecular basis during GBM pathogenesis and oncogenesis is not fully understood, highlighting that it is of great significance to elucidate the molecular mechanisms of GBM initiation and development. Recently, accumulated pieces of evidence have revealed the central roles of long noncoding RNAs (lncRNAs) in the tumorigenesis and progression of GBM by binding with DNA, RNA, or protein. Targeting those oncogenic lncRNAs in GBM may be promising to develop more effective therapeutics. Furthermore, a better understanding of the biological function and underlying molecular basis of dysregulated lncRNAs in GBM initiation and development will offer new insights into GBM early diagnosis and develop novel treatments for GBM patients. Herein, this review builds on previous studies to summarize the dysregulated lncRNAs in GBM and their unique biological functions during GBM tumorigenesis and progression. In addition, new insights and challenges of lncRNA-based diagnostic and therapeutic potentials for GBM patients were also introduced.

Keywords: lncRNA, glioblastoma, diagnostic biomarker, prognostic biomarker, targeted therapy

1 INTRODUCTION

Glioblastoma (GBM) remains one of the most devastating and common malignancies of the central nervous system cancer in adults, and its worse prognosis has not achieved significant improvement despite the development of many new therapeutics (Brennan et al., 2013; Frattini et al., 2013). The median survival time of GBM patients remains only 15 months. Among the developed countries, an estimated more than 3.4 GBM incidents per 100,000 people are diagnosed each year (Ohgaki and Kleihues, 2005). Currently, the standard treatment of GBM is surgical resection followed by radiotherapy with concurrent temozolomide (TMZ)
chemotherapy or adjuvant TMZ chemotherapy. A variety of new inhibitors specifically targeting diverse oncoproteins have been revealed to potently induce GBM regression (Shi et al., 2018; Shi et al., 2019a), but none of them has been approved for clinical applications for GBM therapy. To date, TMZ is still the only one approved by the FDA for GBM chemotherapy. Therefore, it is urgent for clinics to develop more agents for GBM. In addition, the failure of clinical treatments of GBM is attributed to the heterogeneity of GBM (Rusu et al., 2019; Qin et al., 2021) because GBM exhibits a high recurrence rate and frequent resistance to conventional therapeutics owing to tumor cells frequently invading into the surrounding brain, which renders surgical resection virtually impossible (Stupp et al., 2009; Oike et al., 2013). Conventional therapies, including radiotherapy and TMZ-dependent chemotherapy, only target a portion of proliferative cancer cells without harming other cancerous cells owing to the heterogeneity of GBM, which leads to frequent GBM relapse with poor prognosis. Therefore, there is an urgent need to decipher the uniquely biological principles of the initiation and progression of GBM and develop more novel biomarkers and reliable therapeutic targets to overcome this deadly disease.

Over the past several decades, numerous pieces of evidence reported that noncoding RNAs (ncRNAs) play central roles in GBM tumorigenesis and progression (Meller et al., 2015; Rutenberg-Schoenberg et al., 2016; Slack and Chinnaiyan, 2019; Zhu et al., 2021). On the contrary, LncRNAs have switched from transcriptional noise to master epigenetic regulators, and there is an increasing sense that genetic alterations in the noncoding region are the major causes of human disease, including malignant tumors (Maurano et al., 2012). Based on the current knowledge, ncRNAs are classified into two main categories depending on the size of transcripts. Long noncoding RNAs (LncRNAs) are defined as transcripts larger than 200 nucleotides (nt) with limiting or without protein-coding potential, including pseudogenes, lincRNAs, and circRNAs (Slack and Chinnaiyan, 2019; Chen et al., 2020a; Zhan et al., 2020). Notably, LncRNAs account for approximately 80–90% of ncRNAs. LncRNAs have attracted increasing attention for exerting fundamentally regulatory functions in various physiological and pathological processes (Rinn and Chang, 2012; Wahlestedt, 2013; Yin et al., 2015; Schmitt and Chang, 2016).

LncRNA was first identified in 1990 (Brannan et al., 1990a; Gabory et al., 2009). Subsequently, LncRNA XIST was identified to mediate X chromosome inactivation (Shi et al., 2020). At present, abundant genes have been documented to transcribe LncRNA, and this number is still increasing steadily and rapidly (Zhan et al., 2020). An important feature of LncRNAs is that LncRNAs are less conserved across different species and typically expressed lowly and frequently specifically expressed in a certain tissue or different developmental stages, which could be thought to be the most promising biomarkers for GBM diagnosis and prognosis (Gao et al., 2020a; Ghafoori-Fard et al., 2021). Functionally, LncRNA regulates gene expression in cis or in trans by physically interacting with different DNA, RNA, and proteins. Furthermore, with the progress of sequencing technology, the entire spectrum of LncRNAs is gradually investigated, suggesting that LncRNAs could function as not only effective indicators for the early diagnosis and determination of prognosis but also therapeutic targets for GBM. In this review, we introduced the molecular basis of LncRNA and comprehensively summarized the dysregulated LncRNAs involved in GBM tumorigenesis and development. In addition, we also introduced the clinical significance of diagnostic, prognostic, and therapeutic potential of LncRNAs in GBM.

### 2 CLASSIFICATION OF LNCRNA

LncRNAs can be further divided into five categories based on the genomic location relevant to neighboring protein-coding genes (St. Laurent et al., 2015; Peng et al., 2018a): sense LncRNAs (Rinn and Chang, 2012), antisense LncRNAs (Ma et al., 2013), bidirectional LncRNAs (Stackhouse et al., 2020), intronic LncRNAs (Maurano et al., 2012), and intergenic LncRNAs (lincRNAs) (Figure 1A) (Ulitsky and Bartel, 2013). The order of nucleotide arrangement constitutes the primary structure of LncRNAs and the precise secondary and tertiary structures comprise the diversely biological functions of LncRNAs. Based on their subcellular localization (Quinn and Chang, 2016), LncRNAs can be further divided into nuclear or cytoplasmic LncRNAs (Chen, 2016). LncRNAs localized in the nucleus typically regulate gene expression in cis, including transcriptional interference or chromatin remodeling ( Jain et al., 2016; Zhu et al., 2021). On the contrary, LncRNAs localized in the cytoplasm execute regulatory functions via implicating in influencing RNA processing or transport, thereby regulating mRNA degradation or directly altering protein function (Lin et al., 2016). Particular LncRNAs that are represented in a loop pattern, namely, circular RNAs (Meng et al., 2017) and circular intronic RNAs (circRNAs) (Zhang et al., 2013) originated from the back-splicing of exons or introns, respectively (Figure 1B). Notably, circRNAs attracted a great deal of research interest in regulating GBM pathogenesis and oncogenesis (Seimiya et al., 2020; Zhang et al., 2020; Nisar et al., 2021; Xu et al., 2021). Certain primary long noncoding transcripts process special processing, such as alternative splicing, which is an exon inclusion process for LncRNA genesis (Figure 1C). This special processing might offer a new oncogenic driver or tumor-suppressive function for GBM progression. The alternative splicing process events generate new LncRNAs involved in GBM pathogenesis and oncogenesis (Wang et al., 2021; Yang et al., 2021).
3 GENERALLY MOLECULAR BASIS OF LNCRNAS

Since lncRNAs were discovered in 1990, numerous investigations have begun to determine how lncRNAs were involved in regulating signaling transduction in diverse cellular activity and multiple malignant tumor initiation and progression (Kopp and Mendell, 2018). LncRNAs exert their functional roles in regulating multiple biological events through various ways, including binding to DNA, interacting with RNA, and forming an RNA–protein complex through association with proteins (Figures 3, 4). First, chromatin structure and epigenetic modifications are remodeled by lncRNAs binding to DNA and thus affecting the expression of target genes. Second, lncRNAs function as molecular sponges by interacting with mRNAs or miRNAs, thereby mediating the stability and translation of mRNAs or the binding of miRNAs to affect their own target gene expression. Third, lncRNAs are able to bind with proteins to modulate their structural conformation, subcellular localization or stability, and other aspects of functions. We have discussed the functional roles of lncRNA in GBM in detail.

3.1 Transcriptional Activation

It has been widely accepted that many transcription factors are highly expressed in GBM, including SOX2, HIF-1α, and c-Myc (Zhang et al., 2011; Man et al., 2018; Zhou et al., 2016; Zheng et al., 2015; Bae et al., 2021). These transcription factors are not only involved in promoting the initiation of the transcriptional process of protein-coding genes but are also required for the initiative transcription of noncoding genes, including IncRNAs. XISTs were transcribed by general transcription factors involved in controlling gene expression by recruiting specific histone deacetylase to the nucleosomes (Figure 2A). For example, Wang et al. systemically reported that transcription factor HIF-1α was involved in transcribing numerous IncRNAs (Wang et al., 2020a; Liu et al., 2019a; Wang et al., 2020b). GBM is characterized by areas of hypoxia and is associated with worse patient survival. Thus, IncRNAs transcribed by HIF-1α may be partially responsible for HIF-1α–driven GBM progression. Wang et al. reported that PDIA3P1 was induced by HIF-1α and executed as ceRNA to sponge miR-124-3p, consequently promoting epithelial–mesenchymal transition in glioma (Figure 2B) (Wang et al., 2020a). Many lncRNAs have been revealed to be transcriptionally activated by transcription factors that play critical roles in promoting GBM progression, whereas the underlying molecular mechanisms of those IncRNAs in facilitating GBM progression require further study.

3.2 DNA Binding and Chromatin Remodeling

The vast majority of IncRNAs are found to localize in the nucleus, and are commonly found to bind with DNA to regulate gene expression. As mentioned previously, this direct RNA–DNA interaction renders IncRNAs to mediate gene expression in cis (IncRNA and target genes are localized at the same chromosome) or in trans (IncRNA and target genes are localized at different chromosomes); those IncRNAs commonly function as guide IncRNAs. The communication between IncRNAs and well-documented chromatin-associated regulatory complexes is recently further investigated. For example, the lncRNA SWINGN influences the capacity of the SWI/SNF complexes to trigger the epigenetic activation of specific promoters via SMARCB1-dependent activity in topologically organized regions (Grossi et al., 2020). XIST is one of the well-identified lncRNAs that specifically bind with DNA, which modulates X chromosome inactivation during the early developmental progression (Brown et al., 1991) (Figure 2A). To date, accumulated pieces of evidence have reported that multiple IncRNAs execute their biological function by binding with DNA. However, only a small fraction of IncRNA function has been fully elucidated. Shi et al. (2020) suggested that HOTAIRM1 represses the expression of HOXA cluster genes and GBM cell proliferation through the regulation of high-order chromatin structure. Hu et al. revealed that nucleus PLAC2 interacts with STAT1 and activates RPL36 in the transcriptional level by binding RPL36 promoters, but the cytoplasmic IncRNA

![Schematic Illustration of lncRNA species and structures.](Image 89x589 to 506x712)
PLAC2 repressed STAT1 nuclear transfer, consequently reducing RP36 expression, inhibiting glioma cell growth and arresting cell cycle progression (Figure 3A) (Hu et al., 2018a). It is noteworthy that only a small portion of lncRNAs was functionally illustrated to bind with DNA because of the lack of related studies.

### 3.3 miRNA Sponge

As mentioned previously, lncRNAs execute their biological function by interacting with various macromolecules to form RNA complexes. It has been widely studied that miRNA directly interacts with mRNAs to modulate mRNA stability, thereby regulating target gene expression (zur Hausen, 2008; Esquela-Kerscher, 2010). Thousands of lncRNAs have been identified to act as competitive endogenous RNA (ceRNA) by directly binding to miRNAs and affecting their stability; thus, these functional lncRNAs were also termed as miRNA sponges. For example, LncRNA SNHG4 directly binds to miR-138 and promotes GBM cell proliferation via upregulating c-Met, which is a target gene of miR-138 (Wang et al., 2020c). SNHG15 was highly expressed in GBM and promotes tumor angiogenesis by inhibiting the tumor suppressor gene miR-627-5p (Li et al., 2019a). GAPLINC promotes GBM cell proliferation and invasion by sponging miR-331-3p (Chen et al., 2019). LncRNA MALAT1 targets miR-199a and upregulates ZHX1 to promote glioma proliferation and progression (Liao et al., 2019a). Mu et al. suggested that BCYRN1 was the most highly expressed lncRNA in 183 dysregulated lncRNAs. BCYRN1 high expression predicts poor outcomes of glioma patients. BCYRN1 executed its function by sponging miR-619-5p, which was implicated in affecting CUEDC2 expression and the PTEN/AKT/p21 pathway (Mu et al., 2020). Katsushima et al. reported that TUG1 was specifically activated by Notch1 in GSCs coordinately potentiating GSC self-replication maintenance by sponging miR-145 in the cytoplasm and recruiting polycomb protein complexes to repress the expression of several differentiation genes (Katsushima et al., 2016) (Figure 3B).

Liu et al. (2021) reported that PCGEM1 inhibition repressed GBM cell proliferation, migration, invasion, and tumor growth in vivo by promoting CDK6 expression by quenching miR-539-5p. Deguchi et al. (2017) revealed that ECONEXIN as a novel oncogene promotes TOP2A expression by quenching miR-411-5p, which potentiates glioma cell proliferation. In addition, recent studies reported that LINC01094 (Liu et al., 2022), DGCR5 (He et al., 2020a), NFIA-AS2 (Xin et al., 2020),
HANR (Wang et al., 2020d), LINC00355 (Qi et al., 2021), and ZFPM2-AS1 (Zhang et al., 2021) were involved in regulating GBM progression by quenching miR-224-5p, miR-21 and miR-23a, miR-655-3p, miRNA-335, miR-1225, and miR-515-5p, respectively. It is worth stating that numerous other functional lncRNAs, including HOTAIR, GASS, and CASC2, are able to regulate GBM malignant progression by functioning as ceRNA to quench miRNA activity, which has also been reported elsewhere (Peng et al., 2018b; Cheng et al., 2020a; Stackhouse et al., 2020).

3.4 Protein Interaction
Multiple lncRNAs implement their regulatory functions by bonding to RNA binding protein (RBP) and modulating their turnover, implying that lncRNAs hold great potential to serve as therapeutic targets. Given that various similarities existed between lncRNAs and mRNAs, many lncRNAs have been reported to be involved in regulating RBP stability by physical interaction with RBPs. LncRNA MATN1-AS1 binds to E2F6 by competing with RELA and decreased cell proliferation and migration. Kang et al. reported that lncRNA RP11 accelerates p21 degradation and promotes glioma growth by acting as a scaffold protein to physically interact with 14-3-3 β/α, which mediates the degradation of p21 (Kang et al., 2019). Miao et al. revealed that DLGAP1-AS2 promotes glioma cell proliferation, migration, and apoptosis via interacting and regulating YAP1 expression (Miao et al., 2020). Sheng et al. revealed that p53 directly binds to the promoter of ST7-AS1 and activates ST7-AS1 expression at the transcriptional level, which subsequently binds PTBP1 to suppress Wnt/β-catenin signaling and inhibits GBM progression (Sheng et al., 2021). Tang et al. revealed that LINC00115, which is activated by TGF-β, promotes GSC tumorigenicity by augmenting ZNF596 transcription via preventing binding of miR-200s to the 3’-UTR of ZNF596, thereby promoting ZNF596/EZH2/STAT3 signaling axis and GBM tumorogenesis (Yang et al., 2020a). Zhang et al. revealed that ALKBH5 demethylates FOXM1 nascent transcripts, resulting in increased FOXM1 expression. In addition, FOXM1-AS (a long non-coding RNA antisense to FOXM1) triggers the interaction of ALKBH5 with FOXM1 nascent transcripts by directly binding to ALKBH5. Silencing ALKBH5 and FOXM1-AS blocked GSC tumorigenesis by the FOXM1 axis (Zhang et al., 2017a) (Figure 3C). These pieces of evidence suggest that lncRNAs could be involved in signaling transduction by regulating RBP stability, activation, or subcellular localization.

LncRNA was also involved in regulating protein posttranscriptional modification by directly interacting with protein. For instance, Zhu et al. revealed that lnc-β-Catm functions as a scaffold lncRNA to interact with β-catenin and the methyltransferase EZH2, resulting in methylating β-catenin. Methylation of β-catenin inhibits the ubiquitination and β-catenin protein accumulation, thereby activating Wnt/β-catenin signaling and liver CSC self-renewal (Zhu et al., 2016a). Wang et al. suggested that lnc-DC (dendritic cells) interacts directly with STAT3 in the cytoplasm, which leads to enhanced STAT3 phosphorylation on tyrosine-705 via preventing STAT3 binding to and dephosphorylation by SHP1 (Wang et al., 2014). Another study suggested that HIF-1α-induced lncRNA-p21 in the transcriptional level and highly expressed lncRNA-p21 associates with HIF-1α and VHL, thereby leading to disrupting the VHL/HIF-1α protein complex interaction and resulting in attenuating VHL-mediated HIF-1α ubiquitination and degradation, which is essential for hypoxia-mediated glycolysis and cancer progression (Yang et al., 2014). This study highlighted that lncRNA-p21 serves as a valuable therapeutic target for cancer. Furthermore, Sun et al. revealed that lncRNA GClnc1 activates gastric carcinogenesis progression by serving as a modular scaffold of WDR5, which is a key component of histone methyltransferase complex and KAT2A, which consequently leads to altered histone modification pattern (Sun et al., 2016).

As introduced previously, lncRNA is able to serve as an anchoring scaffold by directly binding to the protein complex. For instance, Bian et al. reported that FEZF1-AS1 is capable of binding and enhancing pyruvate kinase 2 (PKM2) protein stability, which causes improved cytoplasmic and nuclear PKM2 levels. Increased cytoplasmic PKM2 boosted pyruvate kinase activity and lactate production, thereby leading to promoting colorectal cancer progression (Bian et al., 2018). However, to the best of our knowledge, there are no GBM-associated lncRNAs involved in protein posttranscriptional regulation. Therefore, it is necessary to explore GBM-associated lncRNAs involved in promoting key protein stability.

3.5 Encoding Small Functional Micro-Peptides
As mentioned above, lncRNAs are defined with transcripts longer than 200 nt and without coding capability. However, much evidence supported that lncRNAs execute their function by encoding functional micropeptides based on their small open-reading frames (sORFs) (Anderson et al., 2015). As mentioned above, lncRNA is able to serve as an anchoring scaffold by directly binding to the protein complex. For instance, Bian et al. reported that FEZF1-AS1 is capable of binding and enhancing pyruvate kinase 2 (PKM2) protein stability, which causes improved cytoplasmic and nuclear PKM2 levels. Increased cytoplasmic PKM2 boosted pyruvate kinase activity and lactate production, thereby leading to promoting colorectal cancer progression (Bian et al., 2018). However, to the best of our knowledge, there are no GBM-associated lncRNAs involved in protein posttranscriptional regulation. Therefore, it is necessary to explore GBM-associated lncRNAs involved in promoting key protein stability.

For example, circular RNA E-cadherin, which is encoded by the E-cadherin variant, promotes GSC tumorigenicity by encoding a small peptide called C-E-Cad, which then binds to EGFR, thereby activating EGFR/STAT3 signaling. Targeting C-E-Cad by an antibody against C-E-Cad inhibits GSC tumorigenic capacity in vivo (Gao et al., 2021) (Figure 3D). Zhang et al. revealed that an 87-amino-acid small peptide encoded by LINC-PINTI regresses GBM cell proliferation in vitro and in vivo by directly interacting with PAF1c and thereby suppressing the transcriptional elongation of various oncogenes (Zhang et al., 2018). These landmark studies open a new direction for the GBM studies and provide more options for developing new therapeutic targets for GBM patients.
3.6 Exosome-Transmitted lncRNA

Exosomes (70–120 nm) are microvesicles that are derived from multivesicular bodies (MVBs) and are secreted into the extracellular milieu after fusion with the cytomembrane (Théry, 2011). Recently, emerging pieces of evidence demonstrated that exosomes can be released from various types of cells and can participate in intercellular communication by transmitting intracellular regulators, such as proteins and nucleic acids, including miRNA and lncRNA (Peinado et al., 2012; Melo et al., 2014). A landmark study from Qu et al. revealed that exosomal IncARSR derived from resistant renal cell carcinoma (RCC) cells could confer sunitinib resistance to endothelial cells by functioning as a ceRNA to quench miR-34 and miR-449, thereby leading to accumulated AXL and c-MET expression. Targeting IncARSR or AXL/c-MET in sunitinib-resistant RCC restores drug sensitivity (Qu et al., 2016). In GBM, exosomes derived from AHIF (Dai et al., 2019), LINC00470 (Ma et al., 2021), and IncSBF2-AS1 reportedly facilitate GBM malignant progression.

4 SIGNIFICANCE OF LCNRNAS IN GBM MALIGNANT PHENOTYPES

Recently, numerous studies documented that multiple dysregulated lncRNAs in GBM are closely associated with GBM tumorigenesis and malignant progression (Yang et al., 2017; Pan et al., 2020; Li et al., 2021). GBM-related lncRNAs that facilitate or repress these malignant behaviors by interplaying with their binding partners are comprehensively summarized as below.

4.1 Gaining GSC Properties

It has been well-proven that a small subset of cancerous cells, termed as the glioma stem cell (GSC) in glioma (Hemmadi et al., 2003; Singh et al., 2003; Singh et al., 2004), bear extremely high tumorigenic potential by replicating rapidly and differentiating into specialized cell types. GSCs have been shown to account for GBM malignant progression, recurrence, and therapeutic resistance (Bao et al., 2006; Chen et al., 2012; Cai et al., 2021). At present, emerging pieces of evidence revealed that lncRNAs were also well-established to be crucially involved in regulating GSC self-renewal maintenance. For example, LINC00115, activated by TGF-β, acts as a miRNA sponge and upregulates ZEB1 by competitively binding to miR-200s, thereby increasing ZEB1 signaling and GSC self-renewal ability (Liu et al., 2019b). In addition, MALAT1 was reported to be enriched in GSC extracellular vesicles compared with GSCs and directly interacts with miR-129-5p, thereby decreasing HMGB1 expression (Yang et al., 2020a). In another study, MALAT1 was reported to promote GSC self-renewal and proliferation by increasing SOX2 expression, which is an important GSC stemness maintenance regulator (Ke et al., 2015). As mentioned above, TUG1 was specifically triggered by Notch1 in to coordinately promote GSC self-renewal by sponging miR-145 in the cytoplasm and recruiting polycomb protein complexes to suppress serval differentiation gene expression (Katsushima et al., 2016). LncRNA XIST was found to potentiate the proliferation of GSCs and regressed their apoptotic rate. More than directly sponging to miR-152, XIST is likely in the same RNA-induced silencing complex (RISC) with miR-152, leading to abrogate miR-152 downstream signaling (Yao et al., 2015). All of these findings suggest that IncRNAs could function as an important regulator in regulating GSC self-renewal and hold tremendous potential to serve as therapeutic targets to specifically eliminate GSCs. Thus, it is of significance to decipher more oncogenic IncRNAs and their molecular basis that promote GSC self-renwal.

4.2 Promoting Uncontrolled Proliferation

Glioma tumorigenesis is a biologically complex process consisting of abnormal activation of oncogenic drivers or loss of function of tumor suppressors (Hanahan and Weinberg, 2000; Chinigò et al., 2021). As mentioned previously, lncRNAs play important roles in regulating the malignant proliferation of GBM or other cancers. For instance, the expression of lncRNA CCND2-AS2 is significantly increased in GBM tissues and cell lines. Targeting CCND2-AS1 represses GBM cell growth and migration through suppressing Wnt/β-catenin signaling (Zhang et al., 2017b). LncRNA NNT-AS1 potentiates glioma cell proliferation via quenching miR-494-3p, resulting in upregulating PRMT1 and promoting GBM progression (Zheng et al., 2020a). As mentioned previously, Deguchi et al. (2017) reported that ECONEXIN is a novel oncogene that promotes TOP2A expression through quenching miR-411-5p, which potentiates glioma cell proliferation. Kang et al. (2019) reported that lncRNA RP11-732M18.3 specifically binds 14-3-3 β/a, which facilitates p21 degradation, thereby promoting GBM cell proliferation (Figure 4). It is worth mentioning that

FIGURE 4 | The functional roles and molecular mechanisms of IncRNAs in sustaining or suppressing GBM malignant progression.
Avoiding cellular apoptosis is another avenue for cancer cells to promote cell proliferation. Recent studies suggested that lncRNAs also play a critical role in cellular apoptosis (Liu and Gu, 2022; Misir et al., 2022; Roberts et al., 2022). For instance, Cheng et al. underscored that STAT1 enhances NKILA expression through binding with the NKILA promoter and consequently transcriptionally activates NKILA expression, which results in regulating T cell sensitivity to activation-induced cell death by inhibiting NF-κB activity by interacting with NF-κB. High expression of NKILA in tumor-specific cytotoxic T lymphocytes and T11 cells is associated with their apoptosis and shorter patient survival (Huang et al., 2018). However, the functional roles of lncRNAs in GBM cell death,
including autophagy, pyroptosis, and ferroptosis, still remain to be understood.

4.3 Activating Invasion and Metastasis

Tumor metastasis remains the leading cause of mortality in cancer patients worldwide. Generally, metastasis is a complicated biological process with numerous stochastic events, including cancer cell migration, local invasion, cancer cell intravasation into the circulation, seed at secondary sites, and formation of clinically detectable metastasis (Lambert et al., 2017; Massagué and Obenauf, 2016). Compelling evidence demonstrated that lncRNAs played critical roles in regulating GBM metastatic progression. For example, lncRNA PDIA3P1, which was activated by hypoxia, and its high expression was correlated with the process of epithelial–mesenchymal transition (EMT) and angiogenesis, and ectopically expressed PDIA3P1 potentiates the migration and invasion capacity of GBM cells (Wang et al., 2020a). Feng et al. recognized that lncRNA-ATB, which is activated by TGF-β, augmented glioma cell invasion mediated by TGF-β through activating p38 signaling (Figure 4) (Tang et al., 2019a). Fu et al. reported that lncRNA PVT1 functions as a ceRNA sponge of miR-128-3p and enhances GBM cell proliferation and invasion by affecting BMP2 and BMP4 expression, which are the core regulators of the BMP signaling pathway (Fu et al., 2018). Zhou et al. recognized that NEAT1 expression was significantly increased in glioma. Targeting NEAT1 regressed glioma cell proliferation, migration, and invasion through sponging miR-132, thereby inhibiting Sox2 expression (Zhou et al., 2018). All of these studies not only provide significant insights into the metastatic progression of biological functions of lncRNAs but also identify new targeted biomarkers, which can be utilized in the targeted therapy for GBM clinical treatment.

EMT is an intricate complex that is required for the invasion of GBM cells and gives rise to a new tumor (Dong et al., 2021). However, the biological function of lncRNAs in the EMT process of GBM remains poorly understood. Recently, Tao et al. screened EMT-associated lncRNAs in TCGA database and found nine EMT-associated lncRNAs and GBM patients with higher EMT-associated lncRNA expression had poorer overall survival (Tao et al., 2021). However, the biological function and underlying molecular basis of EMT-associated lncRNAs still need to be characterized.

4.4 Therapeutic Resistance

Currently, the primary therapy for GBM is TMZ-based chemotherapy or radiotherapy and surgery (Ethun et al., 2017; Han et al., 2020a). As mentioned previously, TMZ is routinely used in glioma patient chemotherapy (Burster et al., 2021). However, the significant challenge of GBM treatments is that the patients eventually develop chemoresistance to TMZ, which consequently causes tumor recurrence. LncRNAs are also involved in TMZ resistance. For instance, lncRNA SOX2OT recruits ALKBH5 to demethylate the SOX2 transcript, thereby leading to increased SOX2 expression, which then promotes GBM cell resistance TMZ treatment (Liu et al., 2020a). Besides the promotion of GBM cell growth and migration, the lncRNA MALAT1 was also documented to be resistant to TMZ in GBM, and silencing MALAT1 sensitizes GBM to TMZ treatment in vitro (Li et al., 2017; Kim et al., 2018). DNA repair protein O-6-methylguanine-DNA methyltransferase (MGMT) plays an important role in TMZ resistance. XIST potentiates the chemoresistance of GBM cells to TMZ by directly quenching and inhibiting miR-29c expression, which then targets SP1 and MGMT and decreases SP1 and MGMT expression. Thus, XIST/ miR-29c may be a potential therapeutic target for glioma treatment (Figure 4) (Du et al., 2017a). LncRNA CASC2 was weakly expressed in GBM, and exogenous CACS2 alone inhibited GBM cell proliferation and amplified TMZ-induced apoptosis of cell proliferation (Liao et al., 2017a). TP73-AS1 amplifies TMZ resistance in GSC and activates metabolism-related gene expression. ALDH1A1 is a biomarker known to be primarily expressed in GSCs and protects GSC from TMZ treatment (Mazor et al., 2019). Silencing SNHG15 in TMZ resistant cells enables GBM cells to be significantly sensitive to TMZ therapy by inhibiting miR-627-5p expression, which results in activation of the CDK6 (Li et al., 2019b). In addition, another report revealed that combining p50 and p53 with the proximal kB and p53 sites of the MALAT1 coding region, thereby increasing the chemosensitivity in turn (Voce et al., 2019). LncSBF2-AS1 was found to be highly expressed in TMZ-resistant GBM cells and tissues, targeting lncSBF2-AS1-sensitized resistant GBM cells to TMZ resistance through serving as ceRNA for sponging miR-151a-3p, resulting in the suppression of its endogenous target, X-ray repair cross-complementing 4 (XRCC4), which increases DNA double-strand break repairability in GBM cells (Zhang et al., 2019). Higher expression of ADAMTS9-AS2 correlated with worse TMZ therapeutic effects and shorter progression-free survival (PFS) in TMZ-treated GBM patients. Silencing of ADAMTS9-AS2 prohibited GBM proliferation, migration, and invasion and decreased the therapeutic effects of TMZ treatment by directly binding to the RRM and Znf_RanBP2 domains of FUS, leading to increased FUS protein expression (Yan et al., 2019). In addition, the involvement of lncRNAs in TMZ resistance is listed in Table 1. As a consequence, it is feasible in clinics to specifically target lncRNAs to offer a fundamental option to overcome TMZ resistance in GBM. LncRNA is involved in TMZ.

Radiotherapy was considered to be the standard therapy for GBM patients. However, its therapeutic benefits are frequently limited with the development of radiotherapy resistance. LncRNAs emerged as regulators in radioresistance (Cardon et al., 2021). Our previous study suggested that high expression of KCNQ1OT1 was observed in stereotactic body radiotherapy-resistant cells and tissues, positively correlated with advanced clinical stage, and lower response rate to concurrent therapy. Silencing KCNQ1OT1 re-sensitized A549/IR and H1975/IR cells to radiation by prohibiting autophagy through sponging miR-372-3p, which directly targets autophagy-related 5 (ATG5) and autophagy-related 12 (ATG12) (He et al., 2020b). Liao et al. suggested that the antisense transcript of hypoxia-inducible factor-1α (AHIF) was highly expressed in GBM cells upon radiotherapy. Targeting AHIF repressed GBM cell clonogenic formation, DNA repair ability, and induced cellular apoptosis.
5.1 Aberrant Expression of lncRNAs in GBM

Ever since the discovery of lncRNA in fetal liver tissue in 1990 (Brannan et al., 1990b), aberrant lncRNA biogenesis has been reportedly observed in the pathogenesis of a variety of diseases, including GBM. In GBM, Mu et al. implemented high-throughput RNA sequencing in three fresh GBM patient specimens and three normal brain tissues from craniocerebral trauma patients and identified that 183 lncRNAs were significantly dysregulated in glioma (Mu et al., 2020). Among the highly expressed lncRNAs, BCYRN1 was recognized to be the most highly expressed in GBM, and further functional studies demonstrated that BCYRN1 significantly promotes GBM cell proliferation and migration (Mu et al., 2020). Li et al. characterized 247 immune-correlated lncRNAs from 529 low-grade glioma samples and five nontumor brain tissue samples in TCGA public database. Cox regression analysis demonstrated that 16 immune-related lncRNA expressions are correlated with identify more GBM immune evasion–associated lncRNA and decode their biological function.

Many studies have shown that cancerous cells are capable of using epigenetic mechanisms to alter their autoimmune origin and destroy the recognition process between tumor cells and the immune system by DNA methylation and histone modifications, which decrease the expression of critical molecules in the immunoreaction process, thereby resulting in disrupting the immune recognition and the failure of immunotherapy (Zang et al., 2018). Currently, many epigenetic inhibitors, including histone deacetylase inhibitors (HDACI), vorinostat (Lee et al., 2012) and valproic acid (Su et al., 2011), or DNA methyltransferase (DNMT) inhibitors, 5-aza-20-deoxycytidine (Garica-Manero et al., 2006), have entered clinical trials either individually or in combination with TMZ for GBM. Thus, the combination of epigenetic drugs and tumor immunotherapy is a promising trend for developing cancer therapy. LncRNAs are critical epigenetic regulators with critical roles in cancer widely participating in epigenetic modification. For instance, Pastori et al. used Helicos single-molecule sequencing to comprehensively profile differentially expressed lncRNAs in GBM, and a subset of GBM-specific lncRNAs regulated by bromodomain and extraterminal (BET) proteins were identified. Treatment of GBM cells with the BET bromodomain inhibitor I-BET151 attenuated oncogenic lncRNA HOTAIR and revitalized a variety of other GBMs decreased lncRNA expression (Pastori et al., 2015).

5 CLINICAL POTENTIAL OF lncRNAs IN GBM

To date, surgical resection is the only likely curative strategy for low-grade glioma, while GBM in the late stage is largely incurable. Thus, new biomarkers and therapeutic targets are urgently required for advancing the diagnosis and clinical therapy of GBM. Here, we summarized the dysregulated lncRNAs in GBM and introduced the diagnostic and prognostic potential of lncRNAs in GBM.
the prognosis in low-grade glioma patients (Li and Meng, 2019). As shown in Table 1, we summarized the dysregulated lncRNAs in glioma and their unique biological significance in glioma occurrence and malignant development. Given the relatively easier examination of lncRNA in GBM patient serum through biopsy, dysregulated lncRNAs may hold the potential to serve as biomarkers to offer a handy and cheap approach for GBM early diagnosis and prognosis. However, to our best knowledge, lncRNA has not been applied in GBM early diagnosis and prognosis at present, highlighting that there is an urgent need to identify more lncRNAs that could steady serve as biomarkers used in GBM clinical diagnosis and prognosis.

5.2 LncRNAs Used as Circulatory Biomarkers

To date, the diagnosis of GBM mainly relies on magnetic resonance imaging. In addition, compared with biopsy of focal tumor lesions, liquid biopsy is noninvasive, therefore, being an ideal diagnostic strategy. Several other tumor-associated lncRNAs can be detected in the body fluid (Huang et al., 2020a). As shown in Figure 5 and Table 2, five lncRNAs were detected to be highly expressed in the serum of GBM patients. For instance, Tan et al. (2018) reported that the serum levels of HOTAIR were markedly higher in GBM patients than in low-grade glioma, with a sensitivity of 86% and specificity of 88%. Cao et al. (2016) showed that the expression of MALAT1 was significantly increased in glioma specimens than in noncancerous brain tissues and MALAT1 expression markedly correlated with glioma grades. Importantly, serum levels of MALAT1 have also been applied in various types of cancer diagnosis and prognosis (Duan et al., 2016; Zhang et al., 2017c). Zhang et al. proposed that GBM cells remodel the tumor microenvironment by enhancing tumor TMZ-resistance through secreting the oncogenic lncSBF2-AS1–enriched exosomes. Therefore, exosomal lncSBF2-AS1 in human serum may act as a possible diagnostic marker for therapy-refractory GBM (Zhang et al., 2019). Clinically, high serum levels of IncSBF2-AS1 in exosomes were found to be correlated with worse responses to TMZ treatment in patients with GBM. Shen et al. also uncovered GASS expression levels in serum samples from 106 GBM patients. The results showed that high GASS expression in level is linked to a decreased likelihood of death, recurrence, and progression (Shen et al., 2018). Moreover, Sun et al. revealed that IncRNA-ANRIL expression levels were remarkably higher in GBM patient serum than in healthy people. The expression of IncRNA-ANRIL was inversely correlated with GBM patient clinical outcomes. Inhibition of IncRNA-ANRIL suppressed GBM cell invasion and avoided cellular apoptosis (Sun et al., 2021). All of these data suggest that serum levels of HOTAIR, MALAT1, IncSBF2-AS1, GASS, IncRNA-ANRIL, and several unidentified IncRNAs have great potential to act as biomarkers utilized for glioma diagnosis and prognosis (Figure 5 and Table 2). However, it is worth mentioning that multiple alternative biomarkers have been proposed and investigated. Nevertheless, clinical trials and prospective validations are required before those can be regarded as clinically viable serum biomarkers for GBM.

5.3 Diagnostic Potentials of lncRNAs in GBM

As previously summarized in Table 1, a large number of lncRNAs, abnormally expressed in glioma as compared with a normal brain, can be used to distinguish glioma patients from healthy cohorts. However, some of those lncRNAs were also documented to be dysregulated in other cancers, such as lung cancer and liver cancer, leading to decreased reliability. Therefore, lncRNAs in combination with other biomarkers, especially the well-known glioma prognostic biomarker, isocitrate dehydrogenase (Hartmann et al., 2009), is more possible to be a favorably diagnostic biomarker instead of evaluating lncRNAs alone. The valuable significance of lncRNAs used in GBM diagnosis and prognosis goes by the fact that lncRNAs are characterized by tissue- and cell-specific expression in a variety of tumors. As previously mentioned, a vast majority of lncRNAs are deregulated in GBM compared with normal brain tissue, which is of clinical significance for the early diagnosis and prognosis of GBM patients. Wang et al. identified 1997 annotated ncRNAs by performing high-throughput microarray in 220 human glioma tissues and found that the expression of HOXA11-AS was dramatically increased in classical and mesenchymal subtype glioma than that in neural and proneural subtypes, indicating that HOXA11-AS holds great potential to act as a useful biomarker for classifying glioma subtypes (Wang et al., 2016a).

To date, surgical resection is the only likely curative strategy for low-grade glioma, while GBM in the late stage is largely incurable. Thus, new biomarkers and therapeutic targets are urgently required for advancing the diagnosis and clinical therapy of GBM. Ever since the discovery of IncRNA in fetal liver tissue in 1990 (Brannan et al., 1990b), aberrant IncRNA biogenesis has been reported to be observed in the pathogenesis of a variety of diseases, including GBM. In GBM, Mu et al. implemented high-throughput RNA sequencing in three fresh GBM patient specimens and three normal brain tissues from craniocerebral trauma patients and identified that 183 IncRNAs were significantly dysregulated in glioma (Mu et al., 2020). Among the highly expressed IncRNAs, BCYRN1 was
recognized as the most highly expressed in GBM, and further functional studies demonstrated that BCYRN1 significantly promotes GBM cell proliferation and migration (Mu et al., 2020). Li et al. characterized 247 immune-correlated IncRNAs from 529 low-grade glioma samples and five nontumor brain tissue samples in TCGA public database. Cox regression analysis demonstrated that 16 immune-related IncRNA expressions are correlated with the prognosis in low-grade glioma patients (Li and Meng, 2019). As shown in Table 1, we summarized the dysregulated IncRNAs in glioma and their unique biological significance in glioma occurrence and malignant development. Given the relatively easier examination of IncRNA in GBM patient serum through biopsy, dysregulated IncRNAs may hold the potential to serve as biomarkers to offer a handy and cheap approach for GBM early diagnosis and prognosis. However, to our best knowledge, IncRNA has not been applied in GBM early diagnosis and prognosis to present, highlighting that there is an urgent need to identify more IncRNAs that could steadily serve as biomarkers used in GBM clinical diagnosis and prognosis.

5.4 Therapeutic Potentials of IncRNAs in GBM

At present, the prognosis of GBM is extremely poor, partially owing to the lack of a therapeutic target. Recently, many studies demonstrated that novel therapeutics targeting IncRNAs are fairly effective in inducing suppression in a variety of tumor types. For example, Liu et al. (2020d) revealed that inhibiting IncRNA AGPG using antisense oligonucleotides (ASO) significantly restrained tumor growth in lung patient-derived xenograft (PDx) models. Xi et al. (2019) recognized that ASO specifically targets LINC02273 dramatically repressed breast cancer invasion and metastasis in vivo. Han et al. (2020c) reported that targeting circLONP2 using ASO substantially inhibits colorectal carcinoma cell invasive ability. These studies revealed that targeting IncRNAs is a new strategy to promote the next generation of cancer therapeutics to advance cancer treatment. However, few efforts have been devoted to the application of ASO-targeted IncRNAs in GBM therapeutic at present (Bennett, 2019; Scoles et al., 2019). The abnormal IncRNA expression level in the specimens of clinical glioma is associated with tumor grades and differentiation status, and both of them have valuable clinical significance in the diagnosis and sub-classification of glioma (Stupp et al., 2009) and prognostication (Rutenberg-Schoenberg et al., 2016; Slack and Chinnaiyan, 2019). Given that GBM is intracranial, the blood–brain barrier (BBB) consists of a specific barrier for drug delivery. The lack of relevant investigation might be attributed to the fact that it is difficult to cross the BBB for IncRNAs. Therefore, chemical modifications of ASO that enable them to counteract the BBB are urgently required for advancing GBM therapy and are of paramount clinical significance to overcome this deadly disease.

A variety of IncRNAs have been documented to play critical roles in the initiation and progression of GBM, which can be utilized as targets for targeted therapy for GBM patients. At present, emerging strategies, including ASOs, locked nucleic acids (LNAs), peptide nucleic acids (PNAs), and morpholino oligonucleotides, have been applied in targeting IncRNAs (Liu et al., 2018; Shahzad et al., 2021). ASOs are single-stranded oligonucleotides with complementary sequences to the target RNAs and repress target RNA biological function by directly binding with partners, which can be used to target mRNAs, miRNAs, IncRNAs, circRNAs, and piRNAs and can be delivered naked without using vehicle delivery (Wang et al., 2019c; Petrescu et al., 2019). As shown in Table 3, ASOs have been documented to execute profound effects in suppressing MALAT1 expression and attenuate GBM cell metastasis and proliferation in vivo (Wan et al., 2014). Morpholinos (MO) are 25-nt nonionic DNA analogs that hybridize to the cognate site of target RNA and trigger target RNA degradation. As revealed by Lu et al., MO delivered via nanoparticles to target IncRNA DANCR in a human ovarian cancer xenograft model convincingly inducing strong repression of tumor growth. However, to the best of our knowledge, there are no studies on the MO used in targeting IncRNA, suggesting that there is an urgent need to apply those advancing strategies in target crucial IncRNAs promoted GBM progression to validate the clinical applications of these IncRNAs in GBM patients. As mentioned in Figure 2D, circRNA E-cadherin is overexpressed in GBM and promotes glioma stem cell tumorigenicity by encoding a small peptide, namely, C-E-Cad. Notably, the inhibition of C-E-Cad exhibits the dramatically antitumor activity via suppressing EGFR signaling in GBM (Gao et al., 2021).

Apart from directly targeting IncRNAs, regulating blood–tumor barrier (BTB) permeability is another way to target GBM. The BTB is a structure that comprises vascular endothelial cells, basement membrane, and glioma cells, which have the capacity to seriously impede the entry of drugs into the tumor microenvironment, leading to extremely unfavorable drug efficacy and worse patient prognosis (Letrado et al., 2018; Vogelbaum, 2018). Given that IncRNAs participate extensively in the malignant progression of GBM, the majority of these IncRNAs are uniquely and differentially expressed in GBM.

### Table 2 | Serum IncRNAs used for diagnosis and prognosis of GBM patients.

| IncRNA       | Prognosis value                                                                                           | Reference                      |
|--------------|------------------------------------------------------------------------------------------------------------|--------------------------------|
| HOTAIR       | Highly expressed in serum level and higher HOTAIR expression associated with worse survival of GBM patients | Tan et al. (2018)              |
| MALAT1       | Highly expressed in serum level and higher MALAT1 expression associated with TMZ resistance                  | Cao et al. (2016)              |
| IncSBF2-AS1  | Highly expressed in serum level                                                                           | Zhang et al. (2019)            |
| GASS         | Highly expressed in serum level and high GASS expression associated with recurrence and progression of GBM patients | Shen et al. (2018)            |
| lncRNA-ANRIL | Highly expressed in serum level and higher ANRIL expression inversely associated with GBM patients’ prognosis | Sun et al. (2021)              |
compared to their corresponding normal tissues (Li et al., 2018). Thus, characterizing compounds or other inhibitors target lncRNAs that influence BBB permeability to enhance chemotherapy and increase drug efficacy is one of the research directions for GBM-targeted therapy. Li et al. revealed that targeting HOTAIR enhances BTB permeability by decreasing miR-148b-3p, leading to a decrease in the expression of GBM-microvascular endothelial cell tight junction by targeting USF1 (Sa et al., 2017). Moreover, BTB permeability was shown to be augmented by silencing LINCO0174 (Shi et al., 2019b), FBXL19-AS1 (Liu et al., 2020e), and Lnc00462717 (Wang et al., 2017) in glioma tissue. Overcoming the obstacle of the BTB to increase the local concentration of chemotherapeutic agents in glioma and thereby increasing therapeutic efficacy is a promising strategy. Therefore, characterizing more appropriate therapeutic targets has been a major concern.

### CONCLUSION AND PERSPECTIVE

GBM is one of the most devastating diseases globally. Therefore, a better understanding of the molecular basis of the initiation and progression of GBM is of great significance to the development of new therapies for patients with GBM. lncRNAs have been well-established to play essential roles in gene regulation and multiple disease initiation and progression. Based on the current knowledge, significant progress has been achieved in characterizing lncRNAs and in deciphering their biological function and clinical potential in GBM occurrence and development over the previous decades. In addition, a variety of lncRNAs were found to function as indispensable factors in the tumorigenesis and progression of GBM. However, several fundamental questions remain to be addressed in the future. First, thousands of characterized lncRNAs have been documented to play key roles in the regulation of gene expression and execute diverse biological activities in a wide range of tumor types at present (Deveson et al., 2017; Hu et al., 2018b), and numerous lncRNAs have been reported to play integral roles in the initiation and development of GBM malignancy, including sustaining stemness, uncontrolled proliferation, invasion, abnormal angiogenesis, and resistance to conventional therapeutics (Peng et al., 2018b). However, among the annotated lncRNAs, only a small proportion of lncRNAs have been functionally recognized, and only a very small proportion of lncRNA-related studies shed new insights into lncRNA biological functions in the initiation and progression of GBM, such as encoding micro-peptides associated with GBM progression, alterations in the processes or structure of proteins, and precisely regulating the tumorigenesis, have not yet been fully understood in GBM pathogenesis (Gibb et al., 2011; Chen and Shen, 2020; Liu et al., 2020f; Yuan et al., 2020). Targeting those oncogenic drivers of GBM may achieve new progress of GBM clinical therapy. Thus, there is still a long way to translate basic scientific discoveries into clinical therapeutics for GBM patients. In addition, given that the dysregulation of lncRNAs and easy detection of lncRNAs through biopsy have great potential to provide novel insight into predictive and prognostic biomarkers for GBM, there is an urgent need to decode those dysregulated lncRNA functions and translate them into biomarkers for glioma patient diagnosis and prognosis.

Second, ceRNA regulatory networks were typically highlighted in the vast majority of GBM-related lncRNA studies, highlighting that it is important to illustrate the functional principles of lncRNAs in GBM. This implies that the current view of the functional role of lncRNAs via competition for miRNAs between RNAs is too simplistic and is essentially required to decode the complicated function by deciphering the other binding partner, such as protein or DNA. In addition, many dysregulated lncRNAs in GBM and the underlying molecular mechanisms still need to be further investigated. Given that lncRNAs primarily execute their functions through binding with other biomolecules, including DNA, RNA, and protein; the senior biological structures of the binding domains are of particular significance. We expect that further studies may be centered on uncovering lncRNA-binding motifs, which could generate more novel RNA-based targets in the development of new therapeutics for cancer treatment.

Third, at present, the therapeutic approaches based on lncRNA structures remain limited in application for the relatively poor stability of lncRNAs. Exosome delivery systems hold the potential to dramatically increase the bioavailability by preserving the integrity of macromolecules, and the engineering of ligand-dependent exosome membranes that specifically target brain tissues is also drawing great interest, leading to targeted therapy being more efficient and specific. It is worth noting that the BBB consists of a specific barrier for drug delivery. Therefore, it is of great significance to develop new drug delivery systems that embody lncRNAs or other compounds that have the capacity to cross the BBB for GBM clinical therapeutics.

Fourth, diverse cancer cells within the same tumors present dramatic genetical and phenotypical distinctions, namely, intratumor heterogeneity. Intratumor heterogeneity is considered an important contributor to glioma progression and therapeutic resistance (Gerlinger et al., 2012). So far, most studies of ceRNA regulation have been performed at a cell-population level. It remains to be elucidated how ceRNA crosstalk differs from cell to cell in a genetically identical or genetically heterogenous population. It also remains unknown how ceRNA regulatory networks rewire during tumor evolution and contribute to the therapeutic resistance mechanism of a

| Targeted lncRNAs | Strategy | Therapeutic effects | Reference |
|------------------|----------|---------------------|-----------|
| MALAT1           | ASO      | Suppressing GBM cell metastasis and proliferation | Wan et al. (2014) |
| circRNA E-cadherin | Monoclonal antibody | Suppressing GSC tumorigenicity | Gao et al. (2021) |
cancer cell. By combining the powerful single-cell techniques (Dalerba et al., 2011; Ramsköld et al., 2012; Wang et al., 2016b), bioinformatics, and mathematical modeling approaches, we may be able to open a new avenue on how lncRNA crosstalk contributes to glioma heterogeneity, which can further boost the clinical implications of lncRNAs.

Herein, we summarize the functional roles of emerging lncRNAs and their underlying mechanisms in the initiation and progression of GBM. Finally, we describe the potential application of lncRNAs in GBM as diagnostic and prognostic biomarkers, as well as the potential therapeutic target of developing lncRNA-targeted therapy.

AUTHOR CONTRIBUTIONS

KL wrote the manuscript and drew the figures. LJ and YL edited and wrote the manuscript. HC and YW made corrections to the manuscript. All the authors read and approved the final version of the manuscript.

REFERENCES

Anderson, D. M., Anderson, K. M., Chang, C.-L., Makarewich, C. A., Nelson, B. R., McAnally, J. R., et al. (2015). A Micropeptide Encoded by a Putative Long Noncoding RNA Regulates Muscle Performance. Cell 160, 595–606. doi:10.1016/j.cell.2015.01.009

Aspden, J. L., Eyre-Walker, Y. C., Phillips, R. J., Amin, U., Muntaz, M. A., Brocard, M., et al. (2014). Extensive Translation of Small Open Reading Frames Revealed by Poly-Ribo-Seq. Elife 3, e03528. doi:10.7554/elife.03528

Bae, W.-Y., Choi, J.-S., Nam, S., and Jeong, J.-W. (2021). Function of LncRNA in Glioblastoma Developing lncRNA-Targeted Therapy. Trends Biochem. Sci. 2021:716462. doi:10.3389/fcell.2021.716462

Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., et al. (2006). Glioma Stem Cells Promote Radiosensitivity by Preferential Activation of the DNA Damage Response. Nature 444, 756–760. doi:10.1038/nature05256

Benett, C. F. (2019). Therapeutic Antisense Oligonucleotides Are Coming of Age. Annu. Rev. Med. 70, 307–321. doi:10.1146/annurev-med-041217-010829

Bian, Z., Zhang, J., Li, M., Feng, Y., Wang, X., Zhang, J., et al. (2018). LncRNA- FEZF1-AS1 Promotes Tumor Proliferation and Metastasis in Colorectal Cancer by Regulating PKM2 Signaling. Clin. Cancer Res. 24, 4808–4819. doi:10.1158/1078-0432.ccr-17-2967

Brannan, C. I., Dees, E. C., Ingram, R. S., and Tilghman, S. M. (1990). The Product of the H19 Gene May Function as an RNA. Mol. Cell. Biol. 10, 28–36. doi:10.1128/mbc.10.1.28

Brannan, C. I., Dees, E. C., Ingram, R. S., and Tilghman, S. M. (1990). The Product of the H19 Gene May Function as an RNA. Mol. Cell. Biol. 10, 28–36. doi:10.1128/mbc.10.1.28

Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., et al. (2013). The Somatic Genomic Landscape of Glioblastoma. Cell 155, 462–477. doi:10.1016/j.cell.2013.09.034

Brown, C. J., Lafreniere, R. G., Powers, V. E., Sebastio, G., Ballabio, A., Pettigrew, A. L., et al. (1991). Localization of the X Inactivation centre on the Human X Chromosome in Xq13. Nature 349, 82–84. doi:10.1038/349802a0

Burster, T., Traut, R., Yermekzyz, Z., Mayer, K., Westhoff, M.-A., Bischof, J., et al.Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells. 9 (2021). doi:10.3389/fcell.2021.695325

Cai, S., Lu, J.-x., Wang, Y.-p., Shi, C.-j., Yuan, T., and Wang, X.-p. (2021). SH2B3, Transcribed by STAT1, Promotes Glioblastoma Progression through Transducing IL-6/gp130 Signaling to Activate STAT3 Signaling. Front. Cell Dev. Biol. 9, 606527. doi:10.3389/fcell.2021.606527

Cao, S., Wang, Y., Li, J., Lv, M., Niu, H., and Tian, Y. (2016). Tumor-suppressive Function of Long Noncoding RNA MALAT1 in Glioma Cells by Suppressing miR-155 Expression and Activating FBXW7 Function. Am. J. Cancer Res. 6, 2561–2574.

Cardon, T., Fournier, I., and Salzet, M. (2021). Unveiling a Ghost Proteome in the Glioblastoma Non-coding RNAs. Front. Cell Dev. Biol. 9, 703583. doi:10.3389/fcell.2021.703583

Chai, Y., Wu, H.-T., Liang, C.-D., You, C.-Y., Xie, M.-X., and Xiao, S.-W. (2020). Exosomal IncRNA ROR1-AS1 Derived from Tumor Cells Promotes Glioma Progression via Regulating miR-4868. Jpn. J. Cancer Res. 15, 8863–8872. doi:10.2147/jncr.s21795

Chen, H. H., Zong, J., and Wang, S. J. (2019). LncRNA GAPLINC Promotes the Growth and Metastasis of Glioblastoma by Sponging miR-331-3p. Eur. Rev. Med. Pharmacol. Sci. 23, 262–270. doi:10.26355/eurrev_201901_16772

Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., et al. (2012). A Restricted Cell Population Propagates Glioblastoma Growth after Chemotherapy. Nature 488, 522–526. doi:10.1038/nature11287

Chen, L.-L. (2016). Linking Long Noncoding RNA Localization and Function. Trends Biochem. Sci. 41, 761–772. doi:10.1016/j.tibs.2016.07.003

Chen, R., Lei, S., Jiang, T., She, Y., and Shi, H. (2020). Regulation of Skeletal Muscle Atrophy in Cachexia by MicroRNAs and Long Non-coding RNAs. Front. Cell Dev. Biol. 8, 577010. doi:10.3389/fcell.2020.577010

Chen, S., and Shen, X. (2020). Long Noncoding RNAs: Functions and Mechanisms in colon Cancer. Mol. Cancer 19, 167. doi:10.1186/s12943-020-01287-2

Chen, Z., Li, S., Shen, L., Wei, X., Zhu, H., Wang, X., et al. (2020). NF-kappa B Interacting Long Noncoding RNA Enhances the Warburg Effect and Angiogenesis and Is Associated with Decreased Survival of Patients with Gliomas. Cell Death Dis 11, 323. doi:10.1038/s41419-020-2520-2

Cheng, J., Meng, J., Zhu, L., and Peng, Y. (2020). Exosomal Noncoding RNAs in Glioma: Biological Functions and Potential Clinical Applications. Mol. Cancer 19, 66. doi:10.1186/s12943-020-01189-3

Cheng, Z., Li, Z., Ma, K., Li, X., Tian, N., Duan, J., et al. (2017). Long Non-coding RNA XIST Promotes Glioma Tumorigenicity and Angiogenesis by Acting as a Molecular Sponge of miR-429. J. Cancer 8, 4106–4116. doi:10.7150/jca.21024

Cheng, Z., Wang, G., Zhu, W., Luo, C., and Guo, Z. (2020). LEF1-AS1 Accelerates Tumorigenesis in Glioma by Sponging miR-489-3p to Enhance HIF1A. Cell Death Dis 11, 690. doi:10.1038/s41419-020-02823-0

Chinigò, G., Castel, H., Chever, O., and Gikà, D., TRP Channels in Brain Tumors. 9 (2021).

Corral-Jara, K. F., Rosas da Silva, G., Fierro, N. A., and Soumelis, V., Modeling the Th17 and Tregs Paradigm: Implications for Cancer Immunotherapy. 9 (2021). doi:10.3389/fcell.2021.675099

FUNDING

This study was supported in part by grants from the National Natural Science Foundation of China (Grant No. 81960551) and the Natural Science Foundation of Yunnan Province (Grant Nos 2016FA038). LJ was also supported by the National Nature Science Foundation of China (81802802) and Yunnan Applied Basic Research Projects (2019FB106).

ACKNOWLEDGMENTS

We apologize to those colleagues whose work was not able to be included in this review due to space limitations.
Gibb, E. A., Brown, C. J., and Lam, W. L. (2011). The Functional Role of Long Non-coding RNA in Human Carcinomas. Mol. Cancer 10, 38. doi:10.1186/1476-4598-10-38

Grossi, E., Raimondi, I., Gotti, E., González, J., Marchese, F. P., Chapaprieta, V., et al. (2020). A lncRNA-SWI/SNF Complex Crosstalk Controls Transcriptional Activation at Specific Promoter Regions. Nat. Commun. 11, 936. doi:10.1038/s41467-020-14623-3

Han, B., Meng, X., Wu, P., Li, Z., Li, S., Zhang, Y., et al. (2020). ATRX/EZH2 Complex Epigenetically Regulates FADD/PARP1 axis, Contributing to TMZ Resistance in Glioma. Theranostics 10, 3351–3365. doi:10.7150/thno.14119

Han, K., Wang, F.-W., Cao, C.-H., Ling, H., Chen, J.-W., Chen, R.-X., et al. (2020). CircLONP2 Enhances Colorectal Cancer Invasion and Metastasis through Modulating the Maturation and Exosomal Dissemination of miRNA-17. Mol. Cancer 19, 60. doi:10.1186/s12943-020-01184-8

Han, M., Wang, S., Fritah, S., Wang, X., Zhou, Y., and Nan, Y., et al. (2020). Interfering with Long Non-coding RNA MR22HG Processing Inhibits Glioblastoma Progression through Suppression of Wnt/β-Catenin Signalling. Brain 143, 512–530. doi:10.1093/brain/awz406

Han, Y., Zhou, L., Wu, T., Huang, Y., Cheng, Z., Li, X., et al. (2016). Downregulation of lncRNA-MALAT1 Affects Proliferation and the Expression of Stemness Markers in Glioma Stem Cell Line SHG1395. Cell Mol Neurobiol 36, 1097–1107. doi:10.1007/s10571-015-0303-6

Hanahan, D., and Weinberg, R. A. (2000). The Hallmarks of Cancer. Cell 100, 57–70. doi:10.1016/s0092-8674(00)81683-9

Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., Christians, A., et al. (2012). Intratumor Heterogeneity and Branched Evolution Revealed by Transcriptome. Trends Genet. 28, 377–388. doi:10.1016/j.tig.2012.02.004

He, H., Song, X., Yang, Z., Mao, Y., Zhang, K., Wang, Y., et al. (2020). Upregulation of KCNQ1OT1 Promotes Resistance to Stereotactic Body Radiotherapy in Lung Adenocarcinoma by Inducing ATG5/ATG12-Mediated Autophagy via miR-372-3p. Cell Death Dis. 11, 883. doi:10.1038/s41419-020-03083-8

He, Z., Long, J., Yang, C., Gong, B., Cheng, M., Wang, Q., et al. (2020). LncRNA DGC5RS Plays a Tumor-Suppressive Role in Glioma via the miR-21-Smad7 and miR-23a/PTEN Axes. Aging 12, 20285–20307. doi:10.18632/aging.103800

Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., Bronner-Fraser, M., et al. (2003). Cancerous Stem Cells Can Arise from Pediatric Brain Tumors. Proc. Natl. Acad. Sci. 100, 15178–15183. doi:10.1073/pnas.2036535100

Hu, X., Sood, A. K., Dang, C. V., and Zhang, L. (2018). The Role of Long Non-coding RNAs in Cancer: the Dark Matter Matters. Curr. Opin. Genet. Dev. 48, 8–15. doi:10.1016/j.gde.2017.10.004

Hu, Y.-W., Kang, C.-M., Zhao, J.-J., Nie, Y., Zheng, L., Li, H.-X., et al. (2018). LncRNA PLAC2 Down-Regulates RPL36 Expression and Blocks Cell Cycle Progression in Glioma through a Mechanism Involving STAT1. J. Cel. Mol. Med. 22, 497–510. doi:10.1111/jcmm.13338

Huang, D., Chen, J., Yang, L., Ouyang, Q., Li, J., Lao, L., et al. (2018). NKILA lncRNA Promotes Tumor Immune Evasion by Sensitizing T Cells to Activation-Induced Cell Death. Nat. Immunol. 19, 1112–1125. doi:10.1038/s41590-018-0207-y

Huang, L., Li, X., Ye, H., Liu, Y., Liang, X., Yang, C., et al. (2020). Long Non-coding RNA NCK1-AS1 Promotes the Tumorigenesis of Glioma through Sponging microRNA-138-2-3p and Activating the TRIM24/Wnt/β-Catenin axis. J. Exp. Clin. Cancer Res. 39, 63. doi:10.1186/s13046-020-01567-1

Huang, Z., Zhou, J.-K., Peng, Y., He, W., and Huang, C. (2020). The Role of Long Non-coding RNAs in Hepatocellular Carcinoma. Mol. Cancer 19, 77. doi:10.1186/s12943-020-01188-4

Ingolia, N. T., Bra, G. A., Stern-Ginossar, N., Harris, M. S., Talhouarne, G. J. S., Jackson, S. E., et al. (2014). Ribosome Profiling Reveals Pervasive Translation outside of Annotated Protein-Coding Genes. Cell Rep. 8, 1365–1379. doi:10.1016/j.celrep.2014.07.045

Jain, A. K., Xi, Y., McCarthy, R., Allton, K., Akdemir, K. C., Patel, L. R., et al. (2016). LncPRESS1 Is a P53-Regulated LncRNA that Safeguards Pluripotency by Disrupting SIRT6-Mediated De-acetylation of Histone H3K56. Mol. Cell 64, 967–981. doi:10.1016/j.molcel.2016.10.039
and Promotes Temozolomide Resistance in Glioblastoma Cancer Stem Cells. *Cell Death Dis* 10, 246. doi:10.1038/s41419-019-1477-5

Meller, V. H., Joshi, S. S., and Deshpande, N. (2015). Modulation of Chromatin by Noncoding RNA. *Annu. Rev. Genet.* 49, 673–695. doi:10.1146/annurev-genet-112414-055205

Melo, S. A., Sugimoto, H., O’Connell, J. T., Kato, N., Villanueva, A., Vidal, A., et al. (2014). Cancer Exosomes Perform Cell-independent microRNA Biogenesis and Promote Tumorigenesis. *Cancer Cell* 26, 707–721. doi:10.1016/j.ccell.2014.09.005

Meng, S., Zhou, H., Feng, Z., Xu, Z., Tang, Y., Li, P., et al. (2017). CircRNA: Functions and Properties of a Novel Potential Biomarker for Cancer. *Mol. Cancer* 16, 94. doi:10.1186/s12943-017-0663-2

Mi, S., Du, J., Liu, J., Hou, K., Ji, H., Ma, S., et al. (2020). FTM Promotes Glioma Tumorigenesis and Angiogenesis via IncRNA SNHG1/miR-9-5p axis. *Cell Signal.* 75, 109749. doi:10.1016/j.cellsig.2020.109749

Miao, W., Li, N., Gu, B., Yi, G., Su, Z., and Cheng, H. (2020). LncRNA DLGAP1-A52 Modulates Glioma Development by Up-Regulating YAP1 Expression. *J. Biochem.* 167, 411–418. doi:10.1093/jb/mvz108

Misir, S., Wu, N., and Yang, B. B. (2022). Specific Expression and Functions of Circular RNAs. Cell Death & Differentiation.

Mu, M., Niu, W., Zhang, X., Hu, S., and Niu, C. (2020). LncRNA BCYRN1 Inhibits Glioma Tumorigenesis by Competitively Binding with miR-619-5p to Regulate CUREC2 Expression and the PTEN/AKT/p70S6 Pathway. *OncoGene* 39, 6879–6892. doi:10.1080/01618432.2020.1814666

Nisar, S., Bhat, A. A., Singh, M., Karedath, T., Rizwan, A., Hashem, S., et al. (2021). Insights into the Role of CircRNAs: Biogenesis, Characterization, *Func. Clin. Impact Hum. Malignancies* 9. doi:10.3389/fcimm.2021.617281

Ohgaki, H., and Kleihues, P. (2005). Population-based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendrogial Gliomas. *J. Neuropathol. Exp. Neurol.* 64, 479–489. doi:10.1093/jnen/64.6.479

Oike, T., Suzuki, Y., Sugawara, K.-i., Shirai, K., Noda, S.-e., Tamaki, T., et al. (2013). Radiotherapy Plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results. *PloS One* 8, e78943. doi:10.1371/journal.pone.0078943

Pan, Y.-B., Zhu, Y., Zhang, Q.-W., Zhang, C.-H., Shao, A., and Zhang, J. (2020). Prognostic and Predictive Value of a Long Non-coding RNA Signature in Glioma: A IncRNA Expression Analysis. *Front. Oncol.* 10, 1057. doi:10.3389/fonc.2020.01057

Pastori, C., Kapranov, P., Pesac, P., Peschansky, V., Volmar, C.-H., Sarkaria, J. N., et al. (2015). The Bromodomain Protein BRD4 Controls HOTAIR, a Long Noncoding RNA Essential for Glioblastoma Proliferation. *Proc. Natl. Acad. Sci. U.S.A.* 112, 8326–8331. doi:10.1073/pnas.1422201112

Pezzella, F., Harris, A. L., Tavassoli, M., and Gatter, K. C. (2015). Blood Vessels and Noncoding RNA Essential for Glioblastoma Proliferation. *Front. Mol. Neurosci.* 8, 38. doi:10.3389/fnmol.2015.00109

Qin, J., Jiang, C., Cai, J., and Meng, X. Roles of Long Noncoding RNAs in Confering Glioma Progression and Treatment. 11 (2021). doi:10.3389/fonc.2021.e68027
GLOSSARY

GBM Glioblastoma
TMZ Temozolomide
ncRNAs Noncoding RNAs
lincRNAs Intergenic lncRNAs
circRNAs Circular Intronic RNAs
cerNA Competitive endogenous RNA
RBP RNA–binding protein
FOXMI-AS A long noncoding RNA antisense to FOXM1
sORFs Open reading frames
GSC Glioma stem cell
MGMT O-6-methylguanine-DNA methyltransferase
GECs Glioma-associated endothelial cells
CXCR7 Chemokine receptor 7b
ASO Antisense oligonucleotides
PDX Patient-derived xenograft
BBB Blood–brain barrier
LNA Locked nucleic acids
PNA Peptide nucleic acids
MO Morpholinos
BTB Blood-tumor barrier
XIST X inactive specific transcript
SOX2 SRY-box transcription factor 2
HIF-1α Hypoxia-inducible factor 1
PDIA3P1 Protein disulfide isomerase family A member 3 Pseudogene 1
TF Transcription factor
SWINGN SWI/SNF interacting GAS6 enhancer noncoding RNA
SMARCB1 SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1
HOTAIRM1 HOXA transcript antisense RNA, myeloid-specific 1
STAT1 Signal transducer and activator of transcription 1
RPL36 Ribosomal protein
SNHG4 Small nucleolar RNA host gene 4
SNHG15 Small nucleolar RNA host gene 15
c-Met MET proto-oncogene, receptor tyrosine kinase
GAPLINC Gastric Adenocarcinoma–associated, positive CD44 regulator, long intergenic noncoding RNA
MALAT1 Metastasis-associated lung adenocarcinoma transcript 1
ZHX1 Zinc fingers and homeoboxes 1
BCYRN1 Brain cytoplasmic RNA 1
CUEDC2 CUE domain containing 2
PTEN Phosphatase and tensin homolog
ADAMTS9-AS2 ADAM metallopeptidase with thrombospondin type 1 motif 9 antisense RNA 2
AKT1 AKT serine/threonine kinase 1
TUG1 Taurine upregulated 1
Notch1 Notch receptor 1
MATN1-AS1 MATN1 antisense RNA 1
E2F6 E2F transcription factor 6
p21 Cyclin-dependent kinase inhibitor 1A
DLGAP1-AS2 DLGAP1 antisense RNA 2
EMT Epithelial-mesenchymal transition
YAP1 Yes1-associated transcriptional regulator
ST7-AS1 ST7 antisense RNA 1
ZNF596 Zinc finger protein 596
EZH2 Enhancer of Zeste 2 polycomb repressive complex 2 subunit
STAT3 Signal transducer and activator of transcription 3
ALKBH5 AlkB homolog 5
FOXM1 Forkhead box M1
EGFR Epidermal growth factor receptor
LINC-PINT Long intergenic non-protein coding RNA, p53 induced transcript
PAF1 Paf1/RNA polymerase II complex component 1
ZEB1 Zinc finger E-box–binding homeobox 1
HMGB1 High mobility group box 1
HOTAIR HOX transcript antisense RNA HOX transcript antisense RNA
NNT-AS1 NNT antisense RNA 1
PRMT1 Protein arginine methyltransferase 1
ECONEXIN long intergenic nonprotein coding RNA 461
TOP2A DNA topoisomerase II alpha
MATN1-AS1 MATN1 antisense RNA 1
ROR1-AS1 ROR1 antisense RNA 1
LEF1-AS1 LEF1 antisense RNA 1
IncrRNA-ATB IncrRNA activated by TGF-beta
BMP4 Bone morphogenetic protein 4
NEAT1 Nuclear paraspeckle assembly transcript 1
PAXIP1AS1 PAXIP1 divergent transcript
KLFI4 Kruppel-like factor 14
Sox2OT SOX2 overlapping transcript
RCC Renal cell carcinoma
HDACI Histone deacetylase inhibitors
DNMT DNA methyltransferase
BET Bromodomain and extraterminal
PCGEM1 Prostate-specific transcript
HNAR Ribosomal protein L13a pseudogene 20
ZFPM2-AS1 ZFPM2 antisense RNA 1
NFIA-AS2 NFIA antisense RNA 2
GAS5 Growth arrest–specific 5 Growth arrest–specific 5
HOTAIR  HOX transcript antisense RNA
DC  Dendritic cells
KCNQ1OT1  KCNQ1 opposite strand/antisense transcript 1
AHIF  Antisense transcript of hypoxia-inducible factor-1α
SP1  Sp1 transcription factor
CASC2  Cancer susceptibility 2
TP73-AS1  TP73 antisense RNA 1
CDK6  Cyclin-dependent kinase 6
H19  H19 imprinted maternally expressed transcript
VASH2  Vasohibin 2
HULC  Hepatocellular carcinoma upregulated long noncoding RNA
PI3K  PI3K phosphatidylinositol 3-kinase
mTOR  Mechanistic target of rapamycin kinase

NKILA  NF-κB-interacting long noncoding RNA
ZNF655  Zinc finger protein 655
USP44  Ubiquitin-specific peptidase 44
PD-L1  Programmed cell death 1 ligand 1
TIM-3  Hepatitis A virus cellular receptor 2
ROR1-AS1  ROR1 antisense RNA 1
TCGA  The Cancer Genome Atlas
HOXA11-AS  HOXA11 antisense RNA
CCND2-AS1  CCND2 antisense RNA 1
GAS5  Growth arrest–specific 5
ANRIL  CDKN2B antisense RNA 1
DANCR  Differentiation antagonizing nonprotein coding RNA
FBXL19-AS1  FRXL19 antisense RNA 1